Korean Genome and Epidemiology Study (KoGES), Ansung-Ansan cohort, South Korea, n=9,248 adults free of CVD/cancer at baseline, mean 7.3y follow-up, 570 incident CVD cases. The paper’s designed focus is the interaction between egg intake and T2DM status on CVD risk (not a post-hoc subgroup cut of a general-population paper). Among participants with T2DM, highest egg intake (~4.2 eggs/week) vs lowest was associated with 2.8x higher CVD incidence (HR 2.81, 95% CI 1.25-6.30, p=0.02); among non-diabetic participants there was no association (HR 1.03, 95% CI 0.77-1.38, p=0.8). Authors conclude higher egg consumption may raise CVD risk specifically in Korean T2DM patients - notable because it is an Asian cohort, i.e. the same population whose general (non-diabetic) egg-T2D association tends to be null/inverse (cf. S-9, S-11), yet shows a large adverse CVD signal restricted to the pre-existing-diabetes subgroup. relevance_note: dedicated diabetic-subgroup CVD-interaction analysis (thread ii), notable for being Asian - shows the “worse in diabetics” pattern is not US-specific.
Methodology
KoGES Ansung-Ansan prospective cohort: 9,248 Korean adults aged 40-69 free of CVD/cancer at baseline, egg intake by FFQ (quartile means ~0.1 / 0.7 / 1.6 / 4.2 servings/week), mean 7.3y follow-up, 570 incident CVD cases. Cox models (Model 4 fully adjusted) for the whole cohort and pre-specified stratification by baseline T2DM status (615 with vs 8,633 without); baseline fasting lipids compared across egg-intake quartiles. The interaction between egg intake and T2DM status on CVD was the paper’s designed primary analysis.
Results
O-72 - KoGES (Korea) - egg intake not associated with CVD incidence in the whole cohort
O-72 — Egg intake quartiles ranged from ~0.1 to ~4.2 servings/week. See
Link to originalMethodology
KoGES Ansung-Ansan prospective cohort: 9,248 Korean adults aged 40-69 free of CVD/cancer at baseline, egg intake by FFQ (quartile means ~0.1 / 0.7 / 1.6 / 4.2 servings/week), mean 7.3y follow-up, 570 incident CVD cases. Cox models (Model 4 fully adjusted) for the whole cohort and pre-specified stratification by baseline T2DM status (615 with vs 8,633 without); baseline fasting lipids compared across egg-intake quartiles. The interaction between egg intake and T2DM status on CVD was the paper’s designed primary analysis.
Link to original
O-73 - KoGES - egg-CVD risk elevated only in the diabetic subgroup (HR 2.81) not in non-diabetics (HR 1.03)
O-73 — The designed focus of the paper (a priori interaction analysis, not a post-hoc subgroup cut). The diabetic-stratum estimate rests on only 79 CVD cases, hence the wide CI.
Link to original
O-74 - KoGES - egg intake not associated with fasting blood lipids across quartiles
O-74 — Cross-sectional baseline biomarkers by egg intake; the adverse CVD signal in diabetics is not accompanied by a detectable lipid difference at the cohort level.
Link to original
Discussion
H-32 - Higher egg consumption raises CVD risk specifically in people with pre-existing T2DM, not in non-diabetics
H-32 — Notable because it is an Asian (Korean) cohort: the same population whose general egg-T2D association tends null/inverse still shows a large adverse egg-CVD signal restricted to diabetics, suggesting the “worse in diabetics” pattern is not US-specific.
Link to original
H-33 - Impaired insulin sensitivity in T2DM deranges cholesterol transport, making egg-derived dietary cholesterol more atherogenic in diabetics
H-33 — Authors’ proposed biological mechanism for the interaction; speculative and not directly tested (no egg-stratified lipid or lipoprotein-subclass data in diabetics).
Link to original
A-24 - Adverse egg-CVD HR confined to the diabetic stratum supports effect-modification by diabetes, but the small subgroup makes it imprecise
Reasoning (A-24): Effect-modification is inferred from the divergence of stratum-specific estimates: a large positive association in diabetics (HR 2.81, p-trend 0.02) versus a flat null in non-diabetics (HR 1.03, p-trend 0.8), which together also explain the near-null whole-cohort estimate (diabetics are a small minority, so their signal is diluted when pooled). This qualitative pattern - risk present in one clinically-defined stratum and absent in the other, with the whole-cohort estimate intermediate/null - is the signature of a true interaction and is what licenses the “harmful specifically in diabetics” reading. Two cautions bound the strength of the inference. (1) Precision: the diabetic stratum contains only 615 people and 79 CVD events across four intake quartiles, so the HR 2.81 has a wide CI (1.25-6.30); with the lower bound so close to 1, the point estimate is likely inflated by the winner’s-curse/low-power dynamic, and the true diabetic effect could be much smaller while still positive. (2) The paper reports the stratum estimates but a formal interaction p-value is not clearly quantified, so the claim rests on the contrast of subgroup HRs rather than a precise interaction test. The direction of the inference (harm concentrated in diabetics) is well supported by the data pattern; the magnitude is not. The argument thus raises the effect-modification hypothesis substantially while flagging that the effect size is uncertain.
Validity (step 6)
status: approved — reason_if_not_false: checked. Traced the step. The conclusion is already the weak/calibrated form: divergence of stratum HRs (2.81 in diabetics vs 1.03 in non-diabetics, whole-cohort null 1.14) “supports inferring” effect-modification and is “plausible yet imprecise and may overstate the true effect size.” Given the premises (the reported stratum estimates), a qualitative stratum divergence is a valid signature of interaction as EVIDENCE, and the whole-cohort null being intermediate is consistently explained by dilution of a small diabetic minority. The obvious undercutting defeater — no formal interaction test, so the divergence could be sampling noise — is not a defeater here because the statement does not claim a proven interaction; it explicitly hedges to “plausible yet imprecise” and separately concedes the magnitude (winner’s-curse inflation, CI 1.25–6.30) is uncertain. Because the claim’s strength is already dialed down to “supports/plausible,” no defeater breaks it; it holds as stated. (Validity only — whether the interaction is real is priced downstream.)
Link to original